dc.contributor.author | Ethiopian Food and Drug Authority | |
dc.date.accessioned | 2024-01-01T06:01:14Z | |
dc.date.available | 2024-01-01T06:01:14Z | |
dc.date.issued | 2021 | |
dc.identifier.uri | http://repository.iphce.org/xmlui/handle/123456789/2682 | |
dc.description.abstract | Ethiopia has successfully managed to lead a well-coordinated response plan including vaccination of COVID-19 vaccines to stop the spread of COVID-19 and address the human and economic impacts on the society. The Ethiopian Food and Drug Authority (FDA) has been working to ensure the availability of quality assured COVID-19 vaccines through providing Emergency Use Authorization (EUA) and monitoring of vaccine safety and conducting Adverse Events Following Immunization (AEFI) surveillances. EFDA has been issuing EUA for COVID 19 vaccine manufacturers as per the requirement of EFDA Guideline for EUA of COVID 19 vaccines. | en_US |
dc.language.iso | English | en_US |
dc.subject | Infectious diseases/COVID-19 | en_US |
dc.title | Risk management plan guideline for COVID-19 vaccines | en_US |
dc.type | Guideline | en_US |